Question 1

Does every project result in a treatment?​

Accepted Answer

Although we do our best to de-risk the approach and maximize the chances of identifying a positive lead molecule, we cannot guarantee it. At Modelis, we place the quality of our science above all else, and sometimes the biology just doesn’t work.

Question 2

Can Modelis help me with an undiagnosed disease?​

Accepted Answer

We can support and assist you in your genetic diagnosis journey. In collaboration with genetic sequencing companies and your healthcare professionals, we can look for a pathogenic mutation in your genome. If you are not currently backed up by a doctor, we can also connect you with medical professionals.

Click here to better understand genetic diagnosis.

Question 3

Are some diseases more important than others?​

Accepted Answer

We do not filter on a specific prevalence whatsoever. If we can do it, we will do it!

Question 4

Why is Modelis’ approach different than other drug discovery projects?​

Accepted Answer

Modelis is rapid and unbiased, meaning we test every molecule we can. We work with living organisms (in vivo), not just cells in a dish. Lastly, we screen thousands of molecules in living organisms, in just a few months (high throughput).

The classical approach usually relies on a specific mechanism (a target) that we suspect to be causing the disease. This approach then looks for specific molecules that would affect this specific mechanism… In contrary, our approach relies on a phenotype-based screening, meaning that we are looking for any molecules that ameliorates the symptoms of our animal models, independently of its potential role in a particular mechanism…

Question 5

Once Modelis has identified a treatment, what’s next?

Accepted Answer

After identifying a promising molecule in our animal models, our main priority is to initiate a clinical trial to validate its effect in humans. Depending of the prevalence of the disease, we can initiate a very small (n-of-1) clinical trial or recruit patients more broadly.

Modelis' has established partnerships with renowned clinicians with an extensive expertise in clinical trial design and development. If we confirm the therapeutic effect of the molecule, we establish a legal strategy to protect our discovery so we can approach larger biotech or pharmaceutical companies to sell them the rights to commercialize the treatment.

Our patient partners are involved all along this process and are a driving force in the clinical development. Our patient partners own part of the intellectual property of their treatment, which is why, they are also rewarded financially in the event of a commercial deal.

thumbnail2.0

Leave a Reply Cancel reply